BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8109822)

  • 1. Immunosuppressive profile of rapamycin.
    Sehgal SN
    Ann N Y Acad Sci; 1993 Nov; 696():1-8. PubMed ID: 8109822
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapamycin: a novel immunosuppressive macrolide.
    Sehgal SN; Molnar-Kimber K; Ocain TD; Weichman BM
    Med Res Rev; 1994 Jan; 14(1):1-22. PubMed ID: 8309312
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapamycin.
    Carlson RP; Sehgal SN; Lewis AJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S129. PubMed ID: 8324938
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapamycin (sirolimus, rapamune).
    Sehgal SN; Camardo JS; Scarola JA; Maida BT
    Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):482-7. PubMed ID: 8591055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
    Morris RE
    Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive drugs.
    Collier SJ
    Curr Opin Immunol; 1989-1990; 2(6):854-8. PubMed ID: 2484794
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapamycin: in vitro profile of a new immunosuppressive macrolide.
    Sehgal SN; Bansbach CC
    Ann N Y Acad Sci; 1993 Jun; 685():58-67. PubMed ID: 8363266
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and mechanism of action of rapamycin in presensitized recipients of experimental allografts.
    Chen H; Wu J; Xu D; Luo H; Daloze P
    Transplant Proc; 1992 Oct; 24(5):1669-70. PubMed ID: 1412790
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases.
    Carlson RP; Baeder WL; Caccese RG; Warner LM; Sehgal SN
    Ann N Y Acad Sci; 1993 Jun; 685():86-113. PubMed ID: 8363289
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacology of rapamycin: a new immunosuppressive agent.
    Chang JY; Sehgal SN
    Br J Rheumatol; 1991; 30 Suppl 2():62-5. PubMed ID: 1993260
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of the proliferation of human thymocytes in vitro by rapamycin.
    Miller GA; Bansbach CC; Rabin M
    Transplantation; 1992 Oct; 54(4):763-5. PubMed ID: 1412778
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action.
    Morris RE
    Ann N Y Acad Sci; 1993 Jun; 685():68-72. PubMed ID: 8363274
    [No Abstract]   [Full Text] [Related]  

  • 15. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of diltiazem and rapamycin on survival of rat cardiac allografts.
    Dumont L; Chen H; Xu D; Daloze P
    Ann N Y Acad Sci; 1993 Nov; 696():392-5. PubMed ID: 8109847
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapamycin inhibits lymphocyte proliferation in a popliteal lymph node model via an IL-2-independent mechanism.
    Warner LM; Lewis GM; Weichman BM; Sehgal SN
    Ann N Y Acad Sci; 1993 Jun; 685():117-20. PubMed ID: 8363215
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 20. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.